Physician profile
David Sauceda
NPI 1912053232
$790.20
in general payments reported to CMS, 2019-2025
15 companies · $296 in 2025
The $296 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.75 · 2020: $93.54 · 2021: $31.27 · 2022: $52.05 · 2023: $78.38 · 2024: $184 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $297.66 | 2021-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $95.36 | 2024-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Ironshore Pharmaceuticals INC. | $84.10 | 2019-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $83.12 | 2019-2025 | Bexsero |
| Alk-Abello, INC | $47.35 | 2025 | Odactra, Ragwitek, Grastek |
| Gm Pharmaceuticals, INC. | $35.19 | 2025 | Vanacof |
| Genentech USA, INC. | $22.12 | 2020 | |
| Tris Pharma INC | $19.80 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.52 | 2023 | |
| Phadia US INC. | $18.25 | 2023 | Immunocap |
| Sanofi Pasteur INC. | $16.76 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $15.42 | 2020 | |
| Collegium Pharmaceutical, INC. | $14.54 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $11.51 | 2021 | |
| Organon LLC | $9.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sauceda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.